Oncotarget

Research Papers:

Analysis of circulating tumor cells from lung cancer patients with multiple biomarkers using high-performance size-based microfluidic chip

Wanlei Gao, Haojun Yuan, Fengxiang Jing, Shan Wu, Hongbo Zhou, Hongju Mao, Qinghui Jin, Jianlong Zhao, Hui Cong and Chunping Jia _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:12917-12928. https://doi.org/10.18632/oncotarget.14203

Metrics: PDF 2673 views  |   HTML 2405 views  |   ?  


Abstract

Wanlei Gao1,3, Haojun Yuan1,3, Fengxiang Jing1, Shan Wu1,2, Hongbo Zhou1, Hongju Mao1, Qinghui Jin1, Jianlong Zhao1, Hui Cong2, Chunping Jia1

1State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai 200050, China

2Center of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, China

3University of Chinese Academy of Sciences, Beijing 100039, China

Correspondence to:

Chunping Jia, email: [email protected]

Hui Cong, email: [email protected]

Keywords: lung cancer, circulating tumor cells, mesenchymal marker, metastasis, size-based microfluidic chip

Received: September 22, 2016    Accepted: November 23, 2016    Published: December 26, 2016

ABSTRACT

Circulating tumor cells (CTCs) have attracted pretty much attention from scientists because of their important relationship with the process of metastasis. Here, we developed a size-based microfluidic chip containing triangular pillar array and filter channel array for detecting single CTCs and CTC clusters independent of tumor-specific markers. The cell populations in chip were characterized by immune-fluorescent staining combining an epithelial marker and a mesenchymal marker. We largely decreased the whole time of detection process to nearly 1.5h with this microfluidic device. The CTCs were subsequently measured in 77 patients with lung cancer and 39 healthy persons. The microfluidic device allowed for the detection of CTCs with apparent high sensitivity and specificity (82.7% sensitivity and 100% specificity). Furthermore, the total CTC counts were found to be elevated in advanced patients with metastases when compared with those without (20.89±14.57 vs 8.428±5.858 cells/mL blood; P<0.01). Combined epithelial marker and mesenchymal marker analysis of CTCs could provide more information about metastasis in patients than only usage of epithelial marker. In conclusion, the development of the size-based microfluidic device for efficient capture of CTCs will enable detailed characterization of their biological properties and values in cancer diagnosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14203